DIA’s Post

📹 In part 4 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA discusses how the organization is looking to expand into different global regions and continue leading awareness for the #clinicalresearch industry

On the blog, our Keith Smith is chatting 5 hot topics for 2024. Learn more and meet us at CosmoProf and MD&M West to continue the conversation. 

There is A LOT to unpack from industry pain points to shipper insights to carrier performance in the upcoming 2024 Annual Benchmark Report. Join Aaron Guild and Ron Taylor on July 16,2024, from 12 pm to 1 pm CDT as they break down the most consequential transportation industry trends and strategies from the 9th Annual Green Mountain Benchmark Report. This webinar will cover: 📍 Market trends 📍 Unique insights for manufacturing, retail, pharmaceutical & technology companies 📍 Challenges and opportunities 📍 Emerging trends and focus areas 📍 Wrap up with Q&A You don’t want to miss this expert deep dive into the critical drivers of your business. Register now -> https://bit.ly/3RMtulR

I enjoyed a recent panel discussion on the future of generics and biosimilars at the recent Medicines for Europe Annual conference in Dublin. Some interesting points came through, especially from Rebecca Guntern, Sandoz CCO and Stephan Eder, EVP Western Europe & Germany at STADA: In short - the industry has all the data it needs to address the challenges we face. What’s needed now is immediate action—especially when it comes to pricing reform and regulatory changes. Pricing structure that incorporates factors such as security of supply, quality, and environmental impact, rather than solely focusing on cost reduction An holistic view must be sought: The need to view healthcare system in its entirety, and the fact that the pharmaceutical sector, whilst a significant factor, cannot shoulder all the cost-cutting pressures alone. This, combined with the importance of collaboration among pharmaceutical companies, even competitors, to share resources, co-develop products, and streamline procurement and distribution...   Listen to the complete webinar here: https://lnkd.in/ePY_pMKk    

Brilliant article from Jill Pearcy at the ABPI. Couldn't agree more. The point about the reach of stories about pharma in TV dramas versus the reach of stories from pharma companies about their achievements is a fundamental reputational challenge. Very interested to see how this dynamic is addressed in the future as these companies and the industry find ways to help people better understand what they do and why they do it. Keen to hear about any parallels that exist. Pharma is such a unique sector. Are there other sectors that have managed to build public familiarity? Are there any that have a public reputation influenced (at least in part) by pop culture that have had their voices heard? Are there any sectors that have successfully told their stories and challenged preconceptions? 

Navigating the biopharma landscape is now a digital journey, and we're at the forefront👨💻💡. Engage with our on-demand webinars to discover success narratives, best practices, and transformative strategies. Watch the webinars on-demand here: https://bit.ly/3RFFohO

Plugging revenue leakage is becoming increasingly important for Life Science companies with escalating pricing pressures and eroding profits in a complex environment driven by increased regulatory pressure and continued concentration of market access intermediaries. Our focus at Quantuvis continues to be to deliver platform solutions to our clients that are informed by Life Science companies in solving for their pertinent and emerging requirements.

One of the most interesting parts of my job is the sheer diversity of challenges I learn about from talking with clients and then working with the excellent Product team at Quantuvis to see what we can solve for in novel ways. This paper focuses on the revenue leakage challenges affecting almost every Life Science company and their teams across Market Access, Pricing & Contracting, and Commercial Analytics.

Our latest report…

The RIM Reference Model is shaping up nicely. Looking forward to the discussion Thursday. We will discuss how to put the model into action to enable regultory reporting and support #fhir based needs like IDMP and ePI. #rim #regulatoryaffairs